Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Paul Curley"'
Autor:
Lee Tatham, Anja Kipar, Jo Sharp, Edyta Kijak, Joanne Herriott, Megan Neary, Helen Box, Eduardo Gallardo Toledo, Anthony Valentijn, Helen Cox, Henry Pertinez, Paul Curley, Usman Arshad, Rajith Kumar Reddy Rajoli, Steve Rannard, James P. Stewart, Andrew Owen
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 8 (2024)
ABSTRACT With some exceptions, global policymakers have recommended against the use of existing monoclonal antibodies in COVID-19 due to loss of neutralization of newer variants. The purpose of this study was to investigate the impact of Ronapreve on
Externí odkaz:
https://doaj.org/article/f7da676fb57b4ce9b203c40c216624a1
Autor:
Eduardo Gallardo-Toledo, Megan Neary, Joanne Sharp, Joanne Herriott, Edyta Kijak, Chloe Bramwell, Paul Curley, Usman Arshad, Henry Pertinez, Rajith K. R. Rajoli, Anthony Valentijn, Helen Cox, Lee Tatham, Anja Kipar, James P. Stewart, Andrew Owen
Publikováno v:
Viruses, Vol 15, Iss 11, p 2161 (2023)
Pibrentasvir (PIB) has been demonstrated to block exonuclease activity of the SARS-CoV-2 polymerase, protecting favipiravir (FVP) and remdesivir (RDV) from post-incorporation excision and eliciting antiviral synergy in vitro. The present study invest
Externí odkaz:
https://doaj.org/article/2abae7604c2149b0bf1d2616a2ba6281
Autor:
Megan Neary, Joanne Sharp, Eduardo Gallardo-Toledo, Joanne Herriott, Edyta Kijak, Chloe Bramwell, Helen Cox, Lee Tatham, Helen Box, Paul Curley, Usman Arshad, Rajith K. R. Rajoli, Henry Pertinez, Anthony Valentijn, Kevin Dhaliwal, Frank Mc Caughan, James Hobson, Steve Rannard, Anja Kipar, James P. Stewart, Andrew Owen
Publikováno v:
Viruses, Vol 15, Iss 8, p 1744 (2023)
The successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention that is implementable alongside vaccination programmes. Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in vitr
Externí odkaz:
https://doaj.org/article/24438ca2f944447a88cab0056c860073
Autor:
Paul Curley, James J. Hobson, Neill J. Liptrott, Edward Makarov, Amer Al-khouja, Lee Tatham, Christopher A. W. David, Helen Box, Megan Neary, Joanne Sharp, Henry Pertinez, David Meyers, Charles Flexner, Caren L. Freel Meyers, Larisa Poluektova, Steve Rannard, Andrew Owen
Publikováno v:
Pharmaceutics, Vol 15, Iss 7, p 1835 (2023)
Long-acting injectable (LAI) formulations promise to deliver patient benefits by overcoming issues associated with non-adherence. A preclinical assessment of semi-solid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) is reported h
Externí odkaz:
https://doaj.org/article/30c9897dc2e441029b763227a146a61d
Autor:
James J. Hobson, Amer Al-khouja, Paul Curley, David Meyers, Charles Flexner, Marco Siccardi, Andrew Owen, Caren Freel Meyers, Steve P. Rannard
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-10 (2019)
Non-adherence to daily drug regimens is responsible for many negative clinical effects including drug resistance in life-long treatments for HIV. Here, the authors report on a HIV prodrug nanoparticle platform for long-acting sustained release of wat
Externí odkaz:
https://doaj.org/article/0af90520fd9449aa84b2d09b2855e9b8
Autor:
Teresa, Brevini, Mailis, Maes, Gwilym J, Webb, Binu V, John, Claudia D, Fuchs, Gustav, Buescher, Lu, Wang, Chelsea, Griffiths, Marnie L, Brown, William E, Scott, Pehuén, Pereyra-Gerber, William T H, Gelson, Stephanie, Brown, Scott, Dillon, Daniele, Muraro, Jo, Sharp, Megan, Neary, Helen, Box, Lee, Tatham, James, Stewart, Paul, Curley, Henry, Pertinez, Sally, Forrest, Petra, Mlcochova, Sagar S, Varankar, Mahnaz, Darvish-Damavandi, Victoria L, Mulcahy, Rhoda E, Kuc, Thomas L, Williams, James A, Heslop, Davide, Rossetti, Olivia C, Tysoe, Vasileios, Galanakis, Marta, Vila-Gonzalez, Thomas W M, Crozier, Johannes, Bargehr, Sanjay, Sinha, Sara S, Upponi, Corrina, Fear, Lisa, Swift, Kourosh, Saeb-Parsy, Susan E, Davies, Axel, Wester, Hannes, Hagström, Espen, Melum, Darran, Clements, Peter, Humphreys, Jo, Herriott, Edyta, Kijak, Helen, Cox, Chloe, Bramwell, Anthony, Valentijn, Christopher J R, Illingworth, Bassam, Dahman, Dustin R, Bastaich, Raphaella D, Ferreira, Thomas, Marjot, Eleanor, Barnes, Andrew M, Moon, Alfred S, Barritt, Ravindra K, Gupta, Stephen, Baker, Anthony P, Davenport, Gareth, Corbett, Vassilis G, Gorgoulis, Simon J A, Buczacki, Joo-Hyeon, Lee, Nicholas J, Matheson, Michael, Trauner, Andrew J, Fisher, Paul, Gibbs, Andrew J, Butler, Christopher J E, Watson, George F, Mells, Gordon, Dougan, Andrew, Owen, Ansgar W, Lohse, Ludovic, Vallier, Fotios, Sampaziotis
Publikováno v:
Nature. 615:134-142
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2)1, could represent a new chemoprophylactic approach for COVID-19 that complements vaccination2,3. However, the mechanisms that control t
Autor:
Owen, Paul Curley, James J. Hobson, Neill J. Liptrott, Edward Makarov, Amer Al-khouja, Lee Tatham, Christopher A. W. David, Helen Box, Megan Neary, Joanne Sharp, Henry Pertinez, David Meyers, Charles Flexner, Caren L. Freel Meyers, Larisa Poluektova, Steve Rannard, Andrew
Publikováno v:
Pharmaceutics; Volume 15; Issue 7; Pages: 1835
Long-acting injectable (LAI) formulations promise to deliver patient benefits by overcoming issues associated with non-adherence. A preclinical assessment of semi-solid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) is reported h
Autor:
Helen Box, Shaun H Pennington, Edyta Kijak, Lee Tatham, Claire H Caygill, Rose C Lopeman, Laura N Jeffreys, Joanne Herriott, Joanne Sharp, Megan Neary, Anthony Valentijn, Henry Pertinez, Paul Curley, Usman Arshad, Rajith KR Rajoli, Steve Rannard, James P. Stewart, Giancarlo A Biagini, Andrew Owen
Antiviral interventions are urgently required to support vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data in support of candidate plausibility are required. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced3ede5533d4549e2592e3ab29697ed
https://doi.org/10.1101/2022.03.03.482788
https://doi.org/10.1101/2022.03.03.482788
Autor:
Lee Tatham, Anja Kipar, Joanne Sharp, Edyta Kijak, Joanne Herriott, Megan Neary, Helen Box, Eduardo Gallardo Toledo, Anthony Valentijn, Helen Cox, Henry Pertinez, Paul Curley, Usman Arshad, Rajith KR Rajoli, Steve Rannard, James Stewart, Andrew Owen
Background: Ronapreve demonstrated clinical application in post-exposure prophylaxis, mild/moderate disease and in the treatment of seronegative patients with severe COVID19 prior to the emergence of the Omicron variant in late 2021. Numerous reports
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb7c2284f120a951e9107933cef0e5d8
https://doi.org/10.1101/2022.01.23.477397
https://doi.org/10.1101/2022.01.23.477397
Autor:
Frank McCaughan, Lee Tatham, Joanne Herriott, Steve P. Rannard, Kevin Dhaliwal, Edyta Kijak, James P. Stewart, Henry Pertinez, Joanne Sharp, Anja Kipar, James J. Hobson, Paul Curley, Andrew Owen, Helen Box, Usman Arshad, Anthony Valentijn, Rajith K. R. Rajoli, Megan Neary
Publikováno v:
bioRxiv
Successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention implementable alongside vaccination programmes. Camostat and nafamostat are serine protease inhibitors that inhibit SARS-CoV-2 viral entry i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::188bacb060485772071766ba5cdf2335
https://doi.org/10.1101/2021.07.08.451654
https://doi.org/10.1101/2021.07.08.451654